Home > Publications database > Radiotherapy Effects on Airway Management in Patients with Nasopharyngeal Cancer. > print

001     294708
005     20251125115901.0
024 7 _ |a 10.3390/cancers16223781
|2 doi
024 7 _ |a pmid:39594736
|2 pmid
037 _ _ |a DKFZ-2024-02441
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Uzun, Davut D
|0 0000-0002-0559-8684
|b 0
245 _ _ |a Radiotherapy Effects on Airway Management in Patients with Nasopharyngeal Cancer.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1732720056_23104
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: At present, there is a paucity of data in the literature pertaining to the impact of radiotherapy (RT) on the success of tracheal intubation in patients with nasopharyngeal cancer (NPC). The aim of this study is to investigate the frequency of difficult tracheal intubation in patients with NPC following RT. Methods: Patients with NPC who underwent RT followed by surgery between 2012 and April 2024 at the University Hospital Heidelberg were retrospectively analyzed. Results: Twenty-three patients, predominantly males (73.9%) with a mean age of 52.9 years, were enrolled. Overall, 65.2% of the patients had an American Society of Anesthesiologists (ASA) class of III. The mean total laryngeal dose was 53.5 Gy for the main and boost plan, and the maximum total laryngeal dose was 66.61 Gy. Direct laryngoscopy was performed in 69.6% of cases, followed by 26.1% videolaryngoscopy, and 4.2% required fiberoptic intubation. In total, 47.8% of the patients had a Cormack/Lehane grade of I, followed by 43.5% with grade II and 8.7% with grade III. Overall, 87% of patients were successfully intubated on the first attempt. Conclusions: It has been demonstrated by previous studies that RT has the potential to enhance complications and difficulties encountered during airway management. While the results must be interpreted with caution, our study provides no evidence of severe impairment in advanced airway management in patients with nasopharyngeal cancer who have undergone radiotherapy.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a airway management
|2 Other
650 _ 7 |a difficult tracheal intubation
|2 Other
650 _ 7 |a laryngoscopy
|2 Other
650 _ 7 |a nasopharyngeal cancer
|2 Other
650 _ 7 |a radiation toxicity
|2 Other
650 _ 7 |a radiotherapy
|2 Other
650 _ 7 |a tracheal intubation
|2 Other
650 _ 7 |a videolaryngoscopy
|2 Other
700 1 _ |a Zimmermann, Timo N
|b 1
700 1 _ |a Schmitt, Felix C F
|0 0000-0001-6464-6191
|b 2
700 1 _ |a Plinkert, Peter K
|b 3
700 1 _ |a Weigand, Markus A
|b 4
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 5
|u dkfz
700 1 _ |a Held, Thomas
|0 0000-0002-3913-4693
|b 6
700 1 _ |a Uzun-Lang, Kristin
|0 0000-0002-5355-3173
|b 7
773 _ _ |a 10.3390/cancers16223781
|g Vol. 16, no. 22, p. 3781 -
|0 PERI:(DE-600)2527080-1
|n 22
|p 3781
|t Cancers
|v 16
|y 2024
|x 2072-6694
856 4 _ |y OpenAccess
|u https://inrepo02.dkfz.de/record/294708/files/cancers-16-03781.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://inrepo02.dkfz.de/record/294708/files/cancers-16-03781.pdf?subformat=pdfa
909 C O |o oai:inrepo02.dkfz.de:294708
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21